SCL Science

SCL Science CapEx/D&A

The CapEx to Depreciation Ratio of SCL Science (246960.KQ) as of Nov 2, 2026 is 5.35. In the previous year, CapEx to Depreciation Ratio was 4.32 — a change of 23.75% (higher).

CapEx/D&A

5.35

YoY

23.75%

Last updated:

CapEx to Depreciation Ratio of SCL Science is 2024 5.35 . CapEx to Depreciation Ratio of SCL Science was 2023 4.32 . It decreases by 23.75% higher compared to the previous year.

The SCL Science CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
0.22 KRW
Jan 1, 2018
0.26 KRW
Jan 1, 2019
1.70 KRW
Jan 1, 2020
7.63 KRW
Jan 1, 2021
16.74 KRW
Jan 1, 2022
1.43 KRW
Jan 1, 2023
4.32 KRW
Jan 1, 2024
5.35 KRW
The SCL Science CapEx/D&A history
YEARCapEx/D&AYoY
5.35+23.75%
4.32+202.92%
1.43-91.47%
16.74+119.60%
7.63+348.87%
1.70+548.16%
0.26+18.40%
0.22-97.36%
8.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

CapEx to Depreciation Ratio of SCL Science is 5.35 in 2024.

CapEx to Depreciation Ratio of SCL Science changed from 4.32 to 5.35, representing a 23.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio SCL Science since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's SCL Science with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SCL Science

All Key Metrics — SCL Science